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ENGLISH SUMMARY 
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease 
characterized by airflow limitation. All patients with relevant respiratory symptoms 
who have been exposed to known risk factors for COPD should be considered for 
diagnostic evaluation. A diagnosis of COPD is based on spirometry. A post-
bronchodilator forced expiratory volume in 1 second/forced vital capacity 
(FEV1/FVC) <0.7 confirms the presence of COPD. It is essential that COPD be 
diagnosed correctly so that appropriate treatment can be initiated. However, COPD 
remains highly underdiagnosed and misdiagnosed. Spirometry, although problematic, 
is the key pulmonary function test in COPD diagnosis and monitoring. The problems 
related to spirometry underline the need for alternative approaches to COPD 
pulmonary function testing. 
The overall aim of this thesis was twofold. First, the thesis aimed to explore the 
challenges of underdiagnosis and misdiagnosis of COPD. Second, the thesis aimed to 
explore alternatives to existing methods of COPD pulmonary function testing. The 
thesis is based on four studies represented in Papers I-IV. Papers I-II addressed the 
first aim of the thesis, whereas Paper III-IV addressed the second aim of the thesis. 
Paper I explored characteristics of patients with undiagnosed COPD. Subjects from 
the National Health and Nutrition Examination Survey (NHANES) (2007-2012) with 
spirometry-based obstruction (n=1098) were included. The subjects were divided into 
two groups: undiagnosed and diagnosed. Various statistical tests were performed to 
compare 51 factors characterizing the two groups. The study found that subjects 
without a COPD diagnosis were characterized by better respiratory health and overall 
health than subjects diagnosed with COPD.  
Paper II explored causes of misdiagnosis of COPD through a scoping review. The 
search of literature was performed in PubMed, EMBASE, and CINAHL. After a 
thorough review process, 73 papers were included in the final sample. The 73 papers 
were synthesized into five themes describing causes of misdiagnosis of COPD. This 
study found that COPD misdiagnosis was mainly caused by factors related to 
spirometry.  
Paper III aimed to improve the spirometry-based diagnosis of COPD by adjusting the 
pre-bronchodilator threshold. Subjects from NHANES (2007-2012) who had 
undergone post-bronchodilator spirometry (n=680) were included. The pre-
bronchodilator threshold was varied while the accuracy, sensitivity, specificity, 
negative predictive value, and positive predictive value were calculated. The results 
showed that an adjustment of the threshold from 0.70 to 0.66 improved classification 
rates potentially minimizing misclassification of COPD.  
Paper IV aimed to validate the Simple Pulmonary Oxygen Transfer Test (SPOT test) 
– a novel pulmonary function test for COPD. Subjects with COPD visiting the 
respiratory medicine clinic at Aalborg University Hospital (n=14) were included. The 
subjects underwent pulmonary function testing including the SPOT test and the test 
of diffusion capacity of the lungs for carbon monoxide (DLCO). Pearson’s product 
moment correlation was used to calculate the correlation between the SPOT test and 
DLCO. The study found a significant correlation between the SPOT test and DLCO 
underlining the potential of the SPOT test as a future pulmonary function test in 
COPD. 
In conclusion, the diagnosis of COPD proves problematic. Patients with undiagnosed 
COPD seems to be characterized by better respiratory health than diagnosed patients. 
Thus, the comprehensive underdiagnosis of COPD may, in part, be explained by the 
fact that respiratory symptoms are mild in the early stages of COPD. The causes of 
misdiagnosis of COPD are many, and they are mainly linked to the key pulmonary 
function test, spirometry. Spirometry is associated with a multitude of biases; in 
particular, the spirometry threshold is much discussed and is a major cause of 
misdiagnosis. An adjustment of the pre-bronchodilator threshold from 0.7 to 0.66 may 
improve COPD diagnosis by limiting misclassification. However, such an adjustment 
is inadequate, and there is a need for alternative pulmonary function tests for COPD. 
The SPOT test shows promise as a new pulmonary function test in COPD. However, 
further studies are needed to ensure the validity and the future role of the SPOT test 
in COPD diagnosis and monitoring. 
 
 
DANSK RESUME 
Kronisk obstruktiv lungesygdom (KOL) er en kronisk lungesygdom, som er 
kendetegnet ved luftvejsobstruktion. Alle patienter med relevante symptomer, som 
har været udsat for kendte risikofaktorer for udvikling af KOL, bør gennemgå 
diagnostisk evaluering. En KOL-diagnose er baseret på spirometri, hvor en 
FEV1/FVC < 0.70 bekræfter diagnosen (spirometrisk sværhedsgrad). Det er af 
afgørende betydning, at KOL diagnosticeres korrekt, således at en passende 
behandling kan igangsættes. Alligevel er KOL i høj grad underdiagnosticeret og 
fejldiagnosticeret. Spirometri er den afgørende lungefunktionstest til anvendelse i 
diagnosticering og monitorering af KOL, på trods af at spirometri medfører en række 
problemer. Disse problemer understreger behovet for at søge alternative muligheder 
inden for lungefunktionstests til patienter med KOL. 
Formålet med denne afhandling var todelt. Først havde afhandlingen til formål at 
undersøge udfordringerne relateret til underdiagnosticering og fejldiagnosticering af 
KOL. Dernæst var formålet med afhandlingen at undersøge alternative muligheder 
inden for lungefunktionstests til patienter med KOL. Afhandlingen blev baseret på 
fire studier, som er repræsenteret i Artikel I-IV. Artikel I-II adresserede afhandlings 
første formål, og Artikel III-IV adresserede afhandlingens andet formål. 
Artikel I undersøgte, hvad der karakteriserede patienter med udiagnosticeret KOL. 
Deltagere fra the National Health and Nutrition Examination Survey (NHANES) 
(2007-2012) med spirometribaseret obstruktion (n=1098) blev inkluderet i studiet. 
Deltagerne blev inddelt i to grupper: Diagnosticerede og udiagnosticerede. Der blev 
foretaget en række statistiske tests med henblik på at sammenligne 51 faktorer, som 
karakteriserede de to grupper. Studiet fandt frem til, at deltagerne uden en KOL-
diagnose var kendetegnet ved bedre lungefunktion og bedre helbred generelt. 
Artikel II undersøgte årsager til fejldiagnosticering af KOL gennem et narrativt 
review. Der blev foretaget en litteratursøgning i PubMED, EMBASE og Cinahl. Efter 
en grundig reviewproces blev 73 artikler inkluderet i studiet. Informationen fra de 73 
artikler blev sammenfattet i fem temaer, som beskrev årsager til fejldiagnosticering af 
KOL. Det blev konkluderet, at årsagerne til fejldiagnosticering først og fremmest var 
knyttet til anvendelsen af spirometri.
 
Artikel III havde til formål at forbedre spirometri-baseret diagnostiering af KOL ved 
at justere grænseværdien for præ-bronkodilaterende spirometri. Deltagere fra 
NHANES (2007-2012), som havde gennemgået post-bronkodilaterende spirometri 
(n=680), blev inkluderet i studiet. Den præ-bronkodilaterende grænseværdi blev 
varieret, mens nøjagtighed, sensitivitet, specificitet, negativ prædiktiv værdi og 
positiv prædiktiv værdi blev udregnet. Resultaterne af studiet viste, at en justering af 
grænseværdien fra 0.70 til 0.66 forbedrede klassificeringsraten og derved potentielt 
begrænsede fejlklassificeringen af KOL. 
Artikel IV havde til formål at validere SPOT-testen, som er en ny lungefunktionstest 
tiltænkt patienter med KOL. Patienter med KOL (n=14) blev inkluderet i studiet på 
Lungemedicinsk Ambulatorium, Aalborg Universitetshospital. Deltagerne 
gennemførte en række lungefunktionstests, herunder SPOT-testen og en diffusionstest 
(DLCO). Pearson’s korrelationskoefficient blev anvendt til at udregne korrelationen 
mellem SPOT-testen og DLCO. Studiet fandt en signifikant korrelation mellem SPOT 
og DLCO, hvilket fremhæver SPOT-testens potentiale som en fremtidig 
lungefunktionstest til patienter med KOL. 
Det kan konkluderes, at diagnosticering af KOL er problematisk. Patienter med 
udiagnosticeret KOL synes at være karakteriseret af bedre respiratorisk helbred end 
patienter med en diagnose. Den omfattende underdiagnosticering af KOL kan til dels 
tilskrives, at respiratoriske symptomer er milde i de tidlige stadier af KOL. Der er 
mange årsager til fejldiagnosticering af KOL. Disse årsager er først og fremmest 
knyttet til spirometri, som er den primære lungefunktionstest inden for KOL. 
Spirometri er associeret med en række bias, og især den spirometriske grænseværdi 
er omdiskuteret og en vigtig årsag til fejldiagnosticering.  En justering af 
grænseværdien for præ-bronkodilaterende spirometri fra 0.70 til 0.66 kan begrænse 
misklassificeringen af KOL og dermed forbedre diagnosticeringen. En sådan justering 
anses dog ikke som værende tilstrækkelig, og der er derfor et behov for alternative 
lungefunktionstests inden for KOL-området. SPOT-testen synes lovende inden for 
diagnosticeringen af KOL. Der er dog behov for yderligere studier, som kan 
undersøge testens validitet og fremtidige rolle inden for diagnosticeringen og 
monitoreringen af KOL. 
PREFACE 
This PhD thesis has been submitted for assessment in fulfillment of the PhD degree 
at the Department of Health Science and Technology, Aalborg University, Denmark. 
The thesis presents the work that has been accomplished during the course of the PhD 
starting January 2014. The PhD was supervised by Ole K. Hejlesen. 
The PhD was conducted in collaboration with the respiratory diseases clinic at 
Aalborg University Hospital, Denmark. Moreover, the PhD student has worked 
extensively with collaborators from the EU-project eWALL, which sponsored the 
PhD study. This international collaboration led to a number of publications that are 
not included in the thesis. 
The thesis is based on four studies conducted during the PhD study. These four studies 
have resulted in four articles, which are presented in the thesis. In addition, the thesis 
includes an introduction and background in which the research field is presented. 
Moreover, the thesis includes a discussion of the presented work, future perspectives, 
and conclusions.  
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CHAPTER 1: INTRODUCTION 
1.1 RATIONALE FOR THE PHD STUDY 
Correct and efficient diagnosis and monitoring are essential for the institution of 
treatment of COPD. However, COPD is often underdiagnosed and misdiagnosed. The 
complexity of COPD should not be underestimated, and COPD is challenging to 
diagnose correctly and monitor efficiently. The challenges related to underdiagnosis 
and misdiagnosis of COPD need further exploration with an eye toward improving 
COPD diagnosis. 
An issue relating to the diagnostic challenges is the lack of an ideal pulmonary 
function test. The most commonly used pulmonary function test in COPD is 
spirometry. However, spirometry proves problematic. Although a COPD diagnosis 
should always be confirmed based on post-bronchodilator spirometry FEV1/FVC, this 
ideal is not always implemented in clinical practice. Based on the challenges linked 
to spirometry, one may consider alternative pulmonary function tests for the diagnosis 
and monitoring of COPD.  
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CHAPTER 2: BACKGROUND 
This chapter describes COPD and its consequences at a societal level as well as at 
an individual level. Moreover, the diagnostic process of COPD and the challenges 
related to underdiagnosis and misdiagnosis are presented. Pulmonary function 
testing and COPD monitoring are also described. 
2.1 SOCIOECONOMIC CONSEQUENCES OF COPD 
Chronic obstructive pulmonary disease (COPD) is a major burden to patients and 
society. The magnitude of this burden is unclear as the global prevalence of COPD is 
hard to verify, mainly due to underdiagnosis and disagreement on the spirometry 
threshold for defining COPD (1). Moreover, data on prevalence rates and incidence 
rates from various countries are lacking (1,2), and the existing predictive data vary in 
quality (3). It has been estimated that approximately 328 million people have COPD 
on a worldwide scale. Various studies of COPD prevalence shows prevalence values 
ranging from 4.5% to 21.5% (1). It is assumed that the prevalence of COPD is 
approximately 10%. The prevalence increases with age, and the prevalence for people 
>70 years old is approximately 15% for women and 20% for men (2). 
Globally, COPD has been ranked the third leading cause of death (4). The COPD 
mortality rate in Europe is approximately 18 per 100,000 inhabitants per year (2). 
However, it should be mentioned that the COPD mortality data may be biased by the 
underdiagnosis of COPD. Moreover, when COPD is the main cause of death, it may 
not always be recognized as such (5).  
COPD represents a major economic burden, mainly due to exacerbations (5). In 
Europe, the average COPD admission rate is approximately 200 per 100,000 people 
per year. More than 50% of patients with COPD who have been admitted due to 
exacerbation are readmitted within a year (2). The total cost of respiratory diseases 
within the EU is estimated to be approximately 6% of the total health care budget. Of 
the cost related to respiratory diseases, 56% (38.6 billion euros) is spent on COPD. In 
the United States, the direct costs of COPD account for an estimated $29.5 billion, 
whereas the indirect costs account for an estimated $20.4 billion (5).  
CHALLENGES AND NEW POTENTIAL IN COPD DIAGNOSIS AND PULMONARY FUNCTION TESTING 
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2.2 COPD CHARACTERISTICS 
COPD is defined as a chronic lung disease that is characterized by persistent airflow 
limitation and respiratory symptoms (3). The airflow limitation is caused by a blend 
of small airways disease and parenchymal destruction, often referred to as chronic 
bronchitis and emphysema, respectively. Inflammatory processes cause narrowing of 
the small airways, destruction of lung parenchyma, and structural changes of both the 
small airways and the alveoli. These structural changes cause gas trapping, airflow 
limitation, hyperinflation, and gas exchange abnormalities (3,5,6).  
COPD is caused by exposure to noxious particles and gases (3). The primary cause of 
COPD is tobacco smoke. Approximately 40-50% of smokers will develop COPD (2). 
Other factors such as occupational exposure, social status, pollution, environmental, 
and genetic factors also add to the risk of developing COPD. Moreover, other 
respiratory diseases such as asthma, chronic bronchitis, and severe respiratory 
infections during childhood add to the risk of developing COPD (2,3). However, 
tobacco smoke remains the primary cause of COPD, accounting for approximately 
75% of cases (2). 
The symptoms of COPD include cough, dyspnea, overproduction of mucus, 
wheezing, and chest tightness (2,3). In the later stages of COPD, fatigue and weight 
loss may occur. Comorbidities are common among patients with COPD and may add 
to the overall severity of the disease. The most common comorbidities include 
anxiety, depression, ischemic heart disease, osteoporosis, and lung cancer (2).  
COPD is characterized by episodic exacerbations during which the respiratory 
symptoms worsen (2). Bacteria and viruses are the most common causes of 
exacerbations. Exacerbations may accelerate the progression of COPD, and these 
episodes thus have a long-lasting negative effect on the health status of patients with 
COPD. Moreover, the risk of dying is increased among patients who suffer from 
exacerbations. There are presumably no current biomarkers that predict COPD 
exacerbations efficiently, although it is highly relevant to identify exacerbations so 
that they can be prevented or treated at an early stage (2,7). Bronchodilators remain 
the primary treatment for exacerbations (7).  
The goals of COPD treatment are many and include reduction of lung function 
decline, prevention of exacerbations, reduction of hospitalizations, reduction of 
mortality, and improvement of quality of life and exercise tolerance (8). The 
management of COPD includes monitoring, reduction of risk factors, stable disease 
management, and exacerbation management (2). Smoking secession is essential for 
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patients who smoke. Moreover, physical exercise plays an important role in the 
management of COPD, as it reduces respiratory symptoms, reduces 
anxiety/depression, and improves physical fitness and quality of life in patients with 
COPD (9). The medical management includes treatment with bronchodilators and 
inhibitors of inflammation. Severely ill patients may be treated with oxygen therapy 
(2). Treatment can improve quality of life, functionality, and life expectancy, as well 
as decrease the level of symptoms (10). 
 
2.3 COPD DIAGNOSIS  
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a 
diagnosis of COPD should be considered in every patient suffering from dyspnea, 
chronic cough, or production of sputum who has been exposed to COPD risk factors 
such as cigarette smoke or environmental pollutants. The primary element in COPD 
diagnosis is the spirometry assessment. A post-bronchodilator forced expiratory 
volume in 1 second/forced expiratory volume (FEV1/FVC)<0.7 confirms COPD 
according to the GOLD definition (5). However, the American College of Physicians 
(ACP), the American College of Chest Physicians (ACCP), the American Thoracic 
Society (ATS), and the European Respiratory Society (ERS) define COPD as airflow 
limitation that is not fully reversible (11,12). Moreover, they prefer to use FEV1/FVC 
below the statistically defined lower fifth percentile of predicted normal values, aka 
the lower limit of normal (LLN), as the decisive threshold for COPD (2). One may 
assume that this disunity regarding the diagnostic threshold may lead to diagnostic 
confusion among primary care physicians, who typically perform the diagnostic 
evaluation. 
 
Spirometry is also an essential element in assessing the severity of COPD, as COPD 
is classified into spirometry-defined severity stages. GOLD and the ATS/ERS have 
not reached a consensus on how to distinguish among the severity stages (3,12). The 
four GOLD stages are most commonly used. However, the ATS and the ERS argue 
that five stages are appropriate when assessing the severity of COPD. Table 1 presents 
the severity stages as defined by GOLD and the ATS/ERS, respectively. The predicted 
reference values are based on height, age, sex, and race (3). 
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Stage ATS/ERS GOLD 
Mild FEV1/VC<5th percentile of 
predicted and FEV1≥70% of 
predicted 
FEV1/FVC<0.7 and FEV1>80% 
of predicted 
Moderate FEV1/VC<5th percentile of 
predicted and FEV1=60-
69% of predicted 
FEV1/FVC<0.7 and 
50%≤FEV1<80% of predicted 
Moderately 
severe 
FEV1/VC<5th percentile of 
predicted and FEV1=50-
59% of predicted 
N/A 
Severe  FEV1/VC<5th percentile of 
predicted and FEV1=35-
49% of predicted 
FEV1/FVC<0.7 and 
30%≤FEV1<50% of predicted 
Very severe FEV1/VC<5th percentile of 
predicted and FEV1<35% of 
predicted 
FEV1/FVC<0.7 and FEV1<30% 
of predicted 
Table 1: The criteria for assessing COPD severity according to the ATS/ERS and GOLD 
(2,3,12). Abbreviations are as follows: ATS: American Thoracic Society; ERS: European 
Respiratory Society; GOLD: Global Initiative for Chronic Obstructive Lund Disease; FEV1: 
forced expiratory volume in 1 second; VC: vital capacity; FVC: forced vital capacity. 
Although spirometry remains the key element in diagnosis of COPD, it should not be 
the only approach used in diagnosing or assessing COPD. GOLD and the ATS/ERS 
agree that the patient’s symptoms and medical history should be included in the 
assessment as well (3,12). Two tests are often used to assess the symptoms: the 
Modified Medical Research Council (mMRC) questionnaire (13) and the COPD 
Assessment Test (CAT)(14). The mMRC questionnaire is a simple tool for assessing 
dyspnea (13), whereas the CAT is an 8-item questionnaire that assesses the impact of 
COPD on a patient’s life (14).  
The risk of exacerbations should also be taken into account in the combined 
assessment of COPD. Finally, additional assessments may be considered, including 
imaging, testing of lung volumes, testing of the diffusion capacity of the lung, pulse 
oximetry, arterial blood gas measurement, assessment of physical activity, and 
exercise tests (3). 
A correct COPD diagnosis is essential for the course of treatment. A false positive 
diagnosis may lead to unnecessary side effects and costs, whereas a false negative 
diagnosis may lead to a lack of relevant treatment as outlined in Figure 1 (15,16). 
However, it has been estimated that more than 50% of the 24 million Americans with 
COPD are either misdiagnosed or undiagnosed (17). 
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Figure 1: Indications for correct diagnosis of COPD. 
 
Diagnosis of COPD is challenging. This challenge may be seen as two-sided as it 
includes underdiagnosis as well as misdiagnosis. As described, numerous patients 
with COPD remain unidentified accounting for the comprehensive underdiagnosis of 
COPD. Moreover, when a patient is actually identified and undergoes diagnostic 
evaluation, errors occur, and patients are misdiagnosed. Both the challenge of 
underdiagnosis and misdiagnosis will be described in the succeeding sections. 
2.3.1 UNDERDIAGNOSIS 
Early diagnosis of patients with COPD is warranted to prevent disease progression, 
reduce exacerbations, and reduce healthcare costs (1,5,18). However, COPD remains 
heavily underdiagnosed (1,19,20). Patients in the early stages of COPD may benefit 
significantly from treatment, as it seems that the most rapid decline in lung function 
in COPD occurs in the moderate stage (21). Smoking cessation reduces lung function 
decline the most at the earlier stages of COPD (22). Thus, it is highly important that 
COPD is identified early to enable early diagnosis. In this way, bronchodilator 
treatment and smoking cessation may be initiated at an earlier disease stage potentially 
altering the progression of COPD and improving quality of life (21,22).  
The underdiagnosis of COPD may be caused by a variety of factors, including lack of 
knowledge and awareness of the disease, lack of believe in the effect of treatment, 
underuse of spirometry, limited respiratory symptoms, etc. (21,23). Limited 
knowledge of COPD and attention to symptoms may cause a delay of COPD diagnosis 
and thereby cause underdiagnosis. It is, of course, difficult to determine a diagnosis 
without any obvious symptoms, which may cause a diagnostic delay until the disease 
has progressed to a more severe level (23). Some patients with clinically relevant 
COPD do not have any respiratory symptoms. For instance, a study by Akamatsu et 
al. (2009) found that 52% of their subjects with a COPD diagnosis had never 
complained of respiratory symptoms (24).  
False positive diagnosis
Unnessessary side effects 
and costs
False negative diagnosis
Lack of treatment
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It is considered highly relevant to reveal the characteristics of patients with COPD 
who remain undiagnosed. Such a revelation would potentially optimize the chances 
of identifying and diagnosing patients with undiagnosed COPD. A few studies have 
explored factors characterizing patients with undiagnosed COPD. However, such 
studies have been inconsistent when it comes to basing their results on post-
bronchodilator spirometry (25,26).  
2.3.2 MISDIAGNOSIS 
When a potential case of COPD is identified and the diagnostic process is completed, 
further challenges arise. The misdiagnosis of COPD is common, and it seems to be 
caused by a multitude of factors. There is ongoing discussion about the ideal 
spirometry threshold to apply in the diagnosis of COPD. The fixed threshold of 0.70 
has been criticized for leading to misdiagnosis of COPD (27,28). In their most recent 
recommendations, GOLD recognizes that the fixed threshold leads to more frequent 
diagnosis among older patients and less frequent diagnosis among younger patients. 
Moreover, spirometry remain underused (29,30), and the spirometry test may be 
biased (31). Thus, the causes of misdiagnosis of COPD are multifaceted, which calls 
for an overview of these causes. 
The diagnostic guidelines are not always followed. Studies have shown that 
bronchodilators are underused (30,32) although diagnostic guidelines clearly describe 
that COPD diagnosis should always be based on post-bronchodilator spirometry (3). 
Arne et al. (2010) found that spirometry data were accessible for only 59% of subjects 
with a recent diagnosis of COPD. Post-bronchodilator spirometry data were accessible 
for only 45% of the same group of subjects. Out of these 45% of subjects with 
accessible post-bronchodilator spirometry data, 34% had a post-bronchodilator 
FEV1/FVC>0.70 (30). These results mirror the findings of Miravittles et al. (2007) 
who found accessible post-bronchodilator spirometry data in 32% of their subjects 
(32). Obviously, this underuse of bronchodilators represents a diagnostic challenge as 
well. This challenge calls for an optimization of pre-bronchodilator-based diagnosis 
of COPD.  
 
2.4 PULMONARY FUNCTION TESTS 
Pulmonary function tests are essential in the diagnosis, monitoring, and management 
of patients with respiratory diseases such as COPD (33). A variety of pulmonary 
function tests may be used to diagnose COPD and assess the severity of the disease. 
In addition to pulmonary function tests, COPD severity may also be assessed using 
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questionnaires, imaging, physical tests, etc. (3). Spirometry and the testing of 
diffusion capacity of the lung for carbon monoxide are described in detail in the 
succeeding sections. 
2.4.1 SPIROMETRY 
Spirometry is the most commonly used pulmonary function test. It measures how a 
subject inhales or exhales volumes of air (3,34). In COPD, spirometry is used to 
measure airflow limitation in a noninvasive manner. Spirometry typically measures 
the volume of air that a subject can exhale (FVC) and the volume of air that a subject 
can exhale in the first second of exhalation (FEV1). The exhalation should be as 
forcefully as possible and start after complete inhalation. Figure 2 illustrates the flow 
of the FEV1/FVC maneuver. The maneuver is repeated three times (34). 
 
Figure 2: The FEV1/FVC maneuver (34). 
Most often, the ratio of FEV1/FVC is calculated (3,34). The results of the spirometry 
test are compared to reference values, which are based on sex, height, and race (3). A 
variety of different spirometers may be used. Continuous quality control of equipment 
and calibration is recommended. The result of a spirometry test will depend on a 
variety of factors, including both personal and technical aspects. The subject and the 
person who performs the examination must cooperate with each other. The subject 
should be verbally encouraged during the examination in an enthusiastic manner using 
both encouraging phrases and body language (34). 
An acceptable spirometry test must have a satisfactory start and a satisfactory end. 
The subject must have understood the instructions and performed the maneuver 
correctly. Seven conditions must be met for a test to be considered acceptable, as 
illustrated in Table 2 (34). 
 
  
Complete 
inhalation
"Blast" of 
exhalation
Complete 
exhalation
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Conditions for acceptable spirometry 
No unsatisfactory start of exhalation (e.g., hesitation) 
No cough affecting the measurement  
No early termination of exhalation 
No Valsalva maneuver or hesitation during the maneuver 
No leak 
No obstructed mouthpiece 
No extra breath during the maneuver 
Table 2: Seven conditions for acceptable spirometry, the FEV1/FVC maneuver (34). 
The repeatability criteria require three acceptable FVC maneuvers for an adequate 
spirometry test. The difference between the highest and the second highest FVC 
should be ≤0.15 L. The difference between the highest and the second highest FEV1 
should also be ≤0.15 L. If the first three maneuvers fail to meet these repeatability 
criteria, more maneuvers should be completed. However, the subject should usually 
not undergo more than eight tries (34). 
A variety of factors may bias the spirometry test, including various technical aspects, 
socioeconomic factors, occupation, gender, body size, age, smoking status, and 
ethnicity (35). Spirometry is inadequate as the only pulmonary function test in COPD, 
and spirometry alone should not be used to monitor disease progression or the impact 
of treatment (6). 
2.4.2 DIFFUSION CAPACITY OF THE LUNG FOR CARBON MONOXIDE 
The diffusion capacity of the lung for carbon monoxide (DLCO) is also known as the 
transfer factor (TLCO). DLCO measures the ability of the airways to exchange gases 
across the alveolar-capillary membrane. This ability is determined by structural as 
well as functional properties (illustrated in Tables 3 and 4) (36). As previously 
described, COPD is characterized by parenchymal destruction (emphysema), where 
the surface area available for diffusion is decreased due to structural changes of the 
lung. When the severity of COPD increases due to more pronounced emphysema, 
DLCO will decrease (37). 
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Structural properties 
Lung gas volume 
Path length for diffusion 
Thickness of the alveolar-capillary membrane  
Area of the alveolar-capillary membrane 
Airway closure 
The hemoglobin volume in the capillaries that supply the alveoli 
Table 3: Structural properties determining the gas exchange capacity of the lung  
 
Functional properties 
Levels of ventilation 
Levels of perfusion 
The uniformity distribution of ventilation vs. perfusion  
Composition of alveolar gas 
Membrane diffusion characteristics 
Properties of hemoglobin in the alveolar capillaries 
The tension of carbon monoxide vs. oxygen in the gas exchange within the alveoli 
Table 4: Functional properties determining the gas exchange capacity of the lung 
All systems used for DLCO are based on the same principles. The system has a source 
of test gas containing 10% helium and 0.3% carbon monoxide (33,36). The test 
measures inhaled and exhaled volume, and the concentration of carbon monoxide and 
tracer gas, respectively. A variety of procedures exists to ensure quality control of the 
systems (36). 
The most commonly used breathing technique for determination of DLCO is the 
single-breath technique (DLCO SB) (38,39). Prior to the test, the patients should be 
instructed thoroughly in all aspects of the test. The subject must be seated comfortably 
and wear a nose clip. The inspiratory maneuvers start with the patient performing tidal 
breathing to ensure that the mouthpiece and nose clip are working properly. The 
DLCO maneuver starts with the patient performing an unforced exhalation to residual 
volume (RV). The exhalation period should not exceed 12 seconds. The patient then 
inhales test gas rapidly to total lung capacity. Next, the patient holds his/her breath for 
10±2 seconds. The breath hold is followed by an exhalation in which the lungs should 
be instantaneously emptied (Figure 3) (36). 
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Figure 3: The DLCO test procedure (36). 
To ensure proper washout of test gas from the lungs, the second test should not be 
performed until at least four minutes after the first test. Moreover, a variety of criteria 
for acceptability should be met as illustrated in Table 5. The repeatability criteria is 
defined as at least two acceptable measurements that lie within 2 mL·min−1·mmHg−1 
(0.67 mmol·min−1·kPa−1). The mean of the results of at least two acceptable 
maneuvers should be reported. There are currently no reliable reference values for 
DLCO (36). 
 
Criteria for acceptability, DLCO 
VI should be ≥90% of the largest VC of the test session. Alternatively, VI should 
be ≥85% of the largest VC of the same session plus VA within 200 mL or 5% of 
the largest VA from other acceptable DLCO maneuvers 
85% of the test gas should be inhaled in <4 seconds 
A stable breath hold should be maintained for 10 ± 2 seconds. No leaks or Valsalva 
or Müller maneuvers  
The collection of the sample should be completed within 4 seconds 
Table 5: Summary of the criteria for acceptability of DLCO (36). VI: Inspiratory volume; VC: 
Vital capacity; VA: Alveolar volume 
 
DLCO is useful as a supplemental pulmonary function test in the diagnosis of COPD. 
Moreover, DLCO is useful in disease monitoring, as changes in DLCO suggest 
changes in lung function (36). However, DLCO is a complex test that requires 
Tidal 
breathing
•Patient performs tidal breathing to ensure that mouthpiece and nose clip 
are working properly
Exhalation
•Patient performs an unforced exhalation to residual volume
Inhalation
•Patient inhales test gas rapidly to total lung capacity
Breathhold
•Patient holds his/her breath for 10±2 seconds
Exhalation
•Patient performs exhalation instantly emptying the lungs
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advanced equipment (38,40). DLCO is associated with bias from a variety of factors, 
including gender, height, ethnic origin, age, hemoglobin, and carboxyhemoglobin 
(35). Moreover, a study by Sansores et al. found that DLCO varied significantly 
during the menstrual cycle (41). Another disadvantage of DLCO is the fact that the 
test is linked to many technical sources of variability including equipment, software, 
test procedures and gases, inspired oxygen pressure, reference equations, and 
atmospheric conditions (35,42). In addition, the variability of DLCO is high (43). 
In summary, there are advances and challenges linked to DLCO as well as spirometry. 
The tests provide insight into two different aspects of the respiration including 
diffusion capacity and airflow. The equipment used for spirometry measurement is 
fairly simple, whereas the equipment used for DLCO is quite complex. Both tests are 
associated with a multitude of bias, which calls for alternative strategies in COPD 
pulmonary function testing. 
 
2.5 COPD MONITORING 
It is essential to follow the progression of COPD in order to minimize or avoid 
exacerbations (7). However, it is not possible to monitor patient symptoms on a 
regular basis at a hospital setting. Various studies have used telemedicine as an 
alternative to conventional treatment (44–46). The World Health Organization 
(WHO) defines telemedicine as follows:   
 “The delivery of health care services, where distance is a critical factor, 
by all health care professionals using information and communication 
technologies for the exchange of valid information for diagnosis, treatment 
and prevention of disease and injuries, research and evaluation, and for the 
continuing education of health care providers, all in the interests of 
advancing the health of individuals and their communities”(47). 
Various telemedicine studies have used different telemedicine setups in the 
monitoring and treatment of patients with COPD aiming to improve quality of 
life, limit exacerbations, minimize hospital admissions, and reduce healthcare 
costs, etc. Telemedicine seems to have a positive effect on quality of life and 
number of visits to the emergency department and the hospital (44). However, 
the evidence within the area of telemedicine is weak (46), and further research 
is requested (44–46).  
The published literature on telemedicine trials shows a great variety in the 
technologies used for the intervention. Spirometry is often not included, and 
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more secondary parameters such as blood saturation, weight, and health-related 
questions are utilized instead (44,45). One may assume that spirometry is 
excluded from the trials because it is too complicated for the test subjects to 
perform the spirometry test without assistance from a healthcare professional 
(34). One may also assume that the ideal COPD telemedicine setup must include 
a pulmonary function test. A pulmonary function test may have the potential of 
optimizing the chances of predicting exacerbations so that early treatment can 
be initiated. However, there are currently no reliable biomarkers that are able to 
predict exacerbations (7). This lack of reliable biomarker to predict 
exacerbations emphasizes the need for an alternative pulmonary function test 
that may able to predict exacerbations in a telemedicine setting. 
 
2.6 SUMMARY OF INTRODUCTION 
In this chapter, COPD and its individual and societal consequences were outlined. 
Moreover, COPD diagnosis and the challenges of underdiagnosis and misdiagnosis 
were highlighted. The underdiagnosis and misdiagnosis of COPD is severe even 
though a correct diagnosis is essential for the course of treatment. More profound 
knowledge regarding characteristics of undiagnosed patients and causes of 
misdiagnosis of COPD would potentially contribute to improve diagnosis of COPD. 
Several pulmonary function tests exist aiming to measure i.e., airflow and the 
diffusion capacity of the lung. However, the existing pulmonary function tests are 
often complex and biased by a variety of factors. These circumstances call for 
alternative approaches in COPD pulmonary function testing.
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CHAPTER 3: AIMS 
This chapter presents the overall aims of the thesis and the research objectives of the 
thesis papers. 
3.1 THESIS AIMS 
The overall aim of the thesis is twofold, as the thesis seeks to cover two areas. First, 
the thesis seeks to gain deeper insight into the problem area. It is well recognized that 
COPD is underdiagnosed as well as misdiagnosed. However, the causes of these 
diagnostic challenges are less clear. Hence, the first aim of the thesis is to explore the 
challenges of underdiagnosis and misdiagnosis of COPD. 
Second, the thesis seeks to explore potential solutions to the challenges identified in 
the first part of the thesis by focusing on pulmonary function testing. Spirometry 
remains the key pulmonary function test in COPD. However, spirometry is associated 
with a multitude of challenges. Hence, the second aim of the thesis is to explore 
alternatives to existing methods in COPD pulmonary function testing. 
Four individual studies represented in four individual papers (I-IV) seek to meet the 
aims of the thesis. Paper I-II address the first thesis aim, whereas Paper III-IV address 
the second thesis aim. The thesis aims and each of their associated papers and research 
objectives are illustrated in Figure 4. 
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Figure 4: The thesis aims and their associated research objectives and papers. 
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CHAPTER 4. SUMMARY OF PAPERS 
This chapter provides a summary of the work conducted in each of the thesis papers 
focusing on the methods and results. 
4.1 PAPER I 
Title: Characteristics of patients with undiagnosed chronic obstructive 
pulmonary disease based on post-bronchodilator spirometry data  
 
Due to a comprehensive underdiagnosis of COPD, it is highly relevant to obtain a 
more profound understanding of the factors that characterize patients with 
undiagnosed COPD. Therefore, this study aimed to explore the characteristics of 
subjects with undiagnosed COPD. 
The study included (n=30,442) subjects from the National Health and Nutrition 
Examination Survey (NHANES) dataset (2007-2012) (48,49). Subjects without 
spirometry-based obstruction and subjects who had not responded to questions 
regarding existing COPD diagnosis were excluded. These criteria resulted in a final 
sample of n=1098 subjects. These subjects had spirometry-based obstruction 
(FEV1/FVC<0.7 or LLN). A previous COPD diagnosis was present in n=93 subjects, 
and no previous COPD diagnosis was present in n=1005 subjects. 
COPD diagnosis was determined solely based on spirometry. The diagnosed subjects 
were defined by a FEV1/FVC<0.7 or LLN combined with a positive response to at 
least one of the questions: “Have you ever been told by a doctor or other healthcare 
professional that you have 1) chronic bronchitis, or 2) emphysema?” The undiagnosed 
subjects were defined by a FEV1/FVC<0.7 combined with a negative response to the 
questions: “Have you ever been told by a doctor or other healthcare professional that 
you have 1) chronic bronchitis, or 2) emphysema?” 
The data was merged and processed using MATLAB (The MathWorks Inc., Natick, 
Massachusetts, United States), and SPSS (IBM Corp., IBM SPSS Statistics, Armonk, 
NY, USA) was used for the statistical analyses. Table 6 illustrates the use of statistical 
tests for the different types of variables.  
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Test Type of variable 
Pearson's chi-squared test Nominal variables 
Mann-Whitney U test  Ordinal variables 
Mann-Whitney U test  Continuous variables that lacked 
normality or homogeneity of variances 
T-test  Continuous variables with normality 
and homogeneity of variance 
Table 6: Overview of the statistical tests used for each type of variable 
 
Fifty-one potential factors characterizing underdiagnosed COPD were tested. 
Bonferroni correction was applied in order to correct for the accumulated probability 
for type 1 error, resulting in a significance level of p<0.001 (p<0.05/51). 
The analysis showed that 13 out of 51 factors characterizing undiagnosed COPD were 
statistically significant (p<0.001). The significant factors are presented in Table 7. 
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Factors characterizing subjects with undiagnosed COPD (p<0.001) 
Less phlegm 
Less wheezing 
Less chest pain 
Less shortness of breath on stairs/inclines 
Fewer work/school days lost to wheezing 
Less sleep disturbance due to wheezing 
Less difficulty socializing 
Less depression 
Less likely to ever have had asthma 
Less likely to have current asthma 
Higher annual household income 
Higher FEV1  
Higher FVC  
Table 7: Statistically significant factors characterizing subjects with undiagnosed COPD 
(p<0.001). 
In conclusion, the results of Paper I showed that a better health condition characterized 
subjects with undiagnosed COPD.   
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4.2 PAPER II 
Title: Causes of misdiagnosis of chronic obstructive pulmonary disease: A 
systematic scoping review 
COPD is highly misdiagnosed. However, to our knowledge, no present study had 
reviewed the existing literature for causes of misdiagnosis of COPD. Thus, this study 
aimed to explore the causes of misdiagnosis of COPD and thereby provide an 
overview of these factors. 
A paper by Green et al. (2006) and the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement served as a guideline for the review 
(50,51). Green et al. (2006), define scoping overviews as “comprehensive narrative 
syntheses of previously published information” (50). Peer-reviewed papers that 
explained causes of misdiagnosis of COPD were included in the review. The criteria 
for inclusion and exclusion are presented in Tables 8 and 9. 
Criteria for inclusion 
Papers explaining misdiagnosis of COPD 
Search period: 1994-2016 
English, German, and all Scandinavian languages 
Peer-reviewed papers 
Table 8: Criteria for inclusion of papers. 
 
Criteria for exclusion 
Papers on misdiagnosis due to lack of spirometry in the diagnosing of COPD 
Papers on underdiagnosis of COPD due to lack of diagnosing 
Table 9: Criteria for exclusion of papers. 
 
A preliminary search gave an overview of the published literature within the area. 
Next, a systematic search was conducted in Medline (PubMed), EMBASE, and 
CINAHL. The search was based on the overall search terms “COPD” and 
“misdiagnosis” supplemented with synonyms, near synonyms, and acronyms. 
Supplemental literature identified by snowballing was also included. 
The review process consisted of multiple steps as illustrated in Figure 5. First, all 
papers were imported into Refworks (ProQuest LLC) where duplicates were removed. 
Subsequently, all titles and abstracts were screened. The remaining papers were then 
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reviewed critically resulting in the final sample of papers. 
 
 
Figure 5: The steps of the review process 
The information identified in the literature search was synthesized into themes. 
Subsequently, the papers were categorized into these themes. The literature search 
identified 1,865 potentially relevant papers. After the review, 73 papers remained 
representing the final sample. The final sample revealed five themes explaining causes 
of misdiagnosis of COPD. The themes are presented in Table 10. 
  
All papers imported into 
Refworks
Duplicates removed
Titles and abstracts 
screened
Critical full paper review
Final sample
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# Incl. (%)  Theme Summary Papers 
1 36 (49) The threshold 
for defining 
COPD 
The fixed threshold causes 
overdiagnosis in older subjects 
and underdiagnosis in younger 
subjects. LLN is suggested as an 
alternative threshold. However, 
LLN may lead to underdiagnosis. 
6,20,58–
67,27,68–
77,28,78–
83,52–57 
2 15 (21) Errors made in 
primary care 
Diagnostic mistakes are more 
often made when a diagnosis is 
established in primary care 
compared to a diagnosis by a 
pulmonary expert.  
23,84,93–
97,85–92 
3 13 (18) Errors linked 
to the spiro-
metry test 
The quality of spirometry testing 
is poor. Some patients are unable 
to perform satisfactory 
spirometry. Physiological 
changes may bias the test. Lack of 
bronchodilators cause 
misdiagnosis. 
57,61,104–
106,75,95,
98–103 
4 10 (14) Differential 
diagnoses 
Patients with comorbidities are 
more often misdiagnosed.  
23,61,96,1
07–113 
5 8 (11) Patient-related 
factors 
Various patient-related factors 
such as sex, ethnicity, drug 
intake, weight, and smoking may 
bias the diagnosis. 
24,74,91,1
14–118 
Table 10: The five themes, their distribution, and their related papers. Incl. (%)=number of 
papers included in the theme. Abbreviation: LLN: lower limit of normal. 
  
In conclusion, this study found that the causes of misdiagnosis of COPD are primarily 
linked to spirometry and to the person performing the diagnosis. 
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4.3 PAPER III 
Title: Increased accuracy after adjustment of spirometry threshold for 
diagnosing COPD based on pre-bronchodilator FEV1/FVC 
Bronchodilators are underused in the diagnosis of COPD. Establishing guidelines for 
COPD diagnosis based on pre-bronchodilator FEV1/FVC may have the potential of 
improving COPD diagnosis. This study aimed to quantify the classification rates 
based on pre-bronchodilator spirometry and to propose an adjustment of the threshold 
for defining COPD based on pre-bronchodilator spirometry. 
The study included subjects from NHANES. Data were merged for 23,433 subjects 
from NHANES 2007-2012 who had undergone post-bronchodilator spirometry. After 
excluding subjects based on the exclusion criteria illustrated in Table 11, 680 subjects 
remained for the analysis. 
Exclusion criteria No. of subjects excluded 
No post-bronchodilator data 21,869 
<40 years of age 807 
Asthma 76 
Lung cancer 1 
Table 11: Criteria for exclusion from the study and the number of subjects excluded for each 
of the criteria 
A COPD diagnosis was determined based on pre-bronchodilator FEV1/FVC. The pre-
bronchodilator diagnosis was then verified as either true or false based on post-
bronchodilator FEV1/FVC. The classification rates were assessed by varying the pre-
bronchodilator threshold while calculating the accuracy, the specificity, the 
sensitivity, the negative predictive value, and the positive predictive value. The 
suggestion for adjustment of the diagnostic threshold for pre-bronchodilator 
FEV1/FVC was based on accuracy. 
The diagnostic accuracy increased from 0.64 to 0.79 when COPD was classified by 
pre-bronchodilator FEV1/FVC<0.66 instead of pre-bronchodilator FEV1/FVC<0.70. 
The results are summarized in Table 12. 
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Pre-bronchodilator 
FEV1/FVC 
 
0.70 
 
0.66 
Accuracy 0.64 0.79 
Sensitivity 1.00 0.75 
Specificity 0.10 0.86 
Negative predictive value 0.96 0.69 
Positive predictive value 0.62 0.89 
Table 12: Classification rates based on pre-bronchodilator FEV1/FVC 0.70 and 0.66. The table 
was adapted and adjusted from Paper III. Abbreviations: FEV1: Forced expiratory volume in 
1 second; FVC: Forced vital capacity. 
In conclusion, it is suggested that the threshold for defining COPD is adjusted to a 
pre-bronchodilator FEV1/FVC<0.66. The pre-bronchodilator FEV1/FVC<0.70 
threshold has poor classification rates and contributes to misclassification of COPD.  
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4.4 PAPER IV: 
Title: A new pulmonary function test for COPD measuring the oxygen transfer 
characteristics of the lung: A proof of concept study 
COPD is complex and difficult to diagnose and monitor using existing pulmonary 
function tests such as spirometry and DLCO. These circumstances call for an 
alternative pulmonary function test. This study aimed to explore the correlation 
between DLCO and the Simple Pulmonary Oxygen Transfer Test (SPOT test) in order 
to validate the SPOT test as a future pulmonary function test for COPD. 
The SPOT test is a pulmonary function test that is currently under development in 
collaboration between Aalborg University and Aalborg University Hospital. The 
SPOT test is based on existing technologies and aims to determine the lung function 
of patients with COPD based on the principles from DLCO. The SPOT test aims to 
minimize complexity and bias known from existing pulmonary function tests and 
measure lung function in a simple and noninvasive manner. 
The specific principles of the SPOT test are described in detail in Paper IV included 
in the full paper version of the thesis. It should, however, be mentioned that the SPOT 
test remains at a preliminary level, and a profound SPOT technology is yet to be 
developed.  
The study was conducted at Aalborg University Hospital at the hospital respiratory 
medicine clinic. All subjects signed informed consent forms, and the local ethical 
committee gave their consent for the study. Clinical staff from the respiratory 
medicine clinic included subjects ≥18 years of age with an existing diagnosis of 
COPD. Twenty subjects were included. However, six subjects were excluded due to; 
measurement error (n=1), lacking signal from pulse oximeter (n=1), FEV1/FVC>0.7 
(n=4). Thus, n=14 subjects remained in the final sample. 
A trained nurse performed body plethysmography (including spirometry) and DLCO 
in accordance with existing guidelines (34,36,119). Researchers from Aalborg 
University performed the SPOT test. The SPOT test was performed twice for each 
subject.  
The results from the two SPOT tests were averaged in the analysis. Pearson’s product 
moment correlation was used to measure the correlation between the SPOT value, 
DLCO SB (% of predicted), and FEV1 (% predicted). DLCO is known to be biased 
by smoking (35). Therefore, an additional analysis was performed in which only the 
n=11 nonsmokers were included.  
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For all 14 subjects, SPOT correlated with DLCO SB (r=-0.730; p=0.003) (Figure 6). 
SPOT and FEV1 did not correlate (r=0.194; p=0.507), and DLCO SB and FEV1 did 
not correlate (r=-0.329; p=0.251). The additional analysis of the 11 nonsmokers also 
showed that SPOT correlated with DLCO SB (r=-0.755; p=0.007). 
 
Figure 6: The correlation of the SPOT test and DLCO. 
In conclusion, the SPOT test shows promise as a COPD pulmonary function test as it 
correlated significantly with DLCO SB. 
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CHAPTER 5: THESIS PAPERS 
This chapter presents the papers that constitute the core of the thesis. The full texts of 
the papers are included in the full version of the thesis. 
5.1 PAPER I 
Characteristics of patients with undiagnosed chronic obstructive pulmonary 
disease based on post-bronchodilator spirometry data 
 
 
Hangaard, Stine; Kronborg, Thomas; Hejlesen, Ole K. (2018) 
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5.2 PAPER II  
Causes of Misdiagnosis of Chronic Obstructive Pulmonary Disease: A 
Systematic Scoping Review  
 
Hangaard, Stine; Helle, Tina; Nielsen, Carl; Hejlesen, Ole K. (2017) 
 
 
 
 
 
 
 
 
 
 
 
Published in Respiratory Medicine, vol. 129, pp. 63-84 
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5.3 PAPER III 
Increased Accuracy after Adjustment of Spirometry Threshold for Diagnosing 
COPD Based on Pre-Bronchodilator FEV1/FVC 
 
Kronborg, Thomas; Hangaard, Stine, Cichosz, Simon Lebech; Hejlesen, Ole 
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5.4 PAPER IV 
A new pulmonary function test for COPD measuring the oxygen transfer 
characteristics of the lung: A proof of concept study 
 
Hangaard, Stine; Kronborg, Thomas; Redke, Finn; Nielsen, Carl; Hejlesen, Ole 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intended for submission to: 
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CHAPTER 6: DISCUSSION 
This chapter begins with a short summary of the main findings of the thesis. The 
summary is followed by methodological considerations. Subsequently, the results of 
the thesis papers are discussed. Finally, the chapter provides suggestions for future 
perspectives. 
6.1 SUMMARY OF THE MAIN FINDINGS 
This PhD study aimed to explore the challenges of underdiagnosis and misdiagnosis 
of COPD and to explore alternative methods in COPD pulmonary function testing. 
Paper I presented characteristics of subjects with undiagnosed COPD. Overall, the 
undiagnosed subjects were characterized by fewer respiratory symptoms and better 
health condition than the subjects who had been diagnosed. The study presented in 
Paper II identified various causes of misdiagnosis of COPD. The causes were mainly 
linked to spirometry. These findings emphasized the call for further investigation of 
alternative methods in COPD pulmonary function testing. Hence, the study presented 
in Paper III aimed to propose an adjustment of the pre-bronchodilator FEV1/FVC 
threshold for diagnosing COPD with an eye to limiting misclassification. The results 
of Paper III showed that an adjustment of the threshold from 0.70 to 0.66 resulted in 
a 15.6% increase in accuracy. However, an adjustment of the threshold does not solve 
the challenge of misdiagnosis of COPD. An alternative pulmonary test may provide a 
more long-term solution to the issues represented by pulmonary function testing in 
COPD. Study IV aimed to explore the correlation between SPOT and DLCO with a 
view to explore the potential of the SPOT test as an alternative pulmonary function 
test for COPD. SPOT correlated significantly with DLCO SB (% of expected), and 
the SPOT test thus shows promising results as a pulmonary function test for COPD.  
 
6.2 METHODOLOGICAL CONSIDERATIONS  
Each of the thesis studies have strengths and limitations, which will be elaborated in 
this section. 
 
6.2.1 PAPER I 
Paper I contributed information regarding the characteristics of undiagnosed COPD. 
A strength of the study presented in Paper I was that a relatively high number of 
characteristics of undiagnosed COPD were explored. However, additional potential 
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characteristics such as edema, peptic ulcer, history of lower tract infection, etc. were 
not explored as they were not included in the NHANES survey. 
The study presented in Paper I is limited by the fact that a COPD diagnosis was solely 
presumed for the subjects who responded positively to whether they had been told 
that they had emphysema or chronic bronchitis. Thus, some subjects may have 
answered incorrectly, which would result in an incorrect classification as either 
undiagnosed or diagnosed. In addition, the study is limited by the fact that the 
diagnosis is based on spirometry alone. However, these diagnostic limitations were 
accommodated by using the same procedure for defining COPD as similar studies 
(25,120). The study had a very high rate of underdiagnosis among the included 
subjects as 91.53% of the subjects reported no previous diagnosis of COPD. This 
unusually high rate may partly be explained by the diagnostic criteria selected for the 
study. However, the high rate may also be explained by the fact that the subjects had 
only mild respiratory symptoms, hindering an early diagnosis.  
 
Another limitation of the study is that subjects with severe COPD may be less inclined 
to participate in a survey such as NHANES. Thus, the sample may not represent all 
COPD severity grades. 
 
6.2.2 PAPER II 
Paper II contributed an overview of previously published literature describing causes 
of misdiagnosis of COPD. A general strength of scoping reviews is that they are 
particularly useful for allowing synthesizing of comprehensive topics (121). Paper II 
was conducted based on guidelines provided by Green et al. (2006) and PRISMA to 
ensure a systematic methodological approach of high quality (50,51). Moreover, 
Paper II was strengthened by the fact that the second author of Paper I validated the 
final sample of papers. 
 
A general limitation of scoping reviews is that the papers are not assessed for quality. 
Thus, the strength of the studies is not taken into account. The search of literature was 
performed in three medical databases (PubMed, EMBASE, and Cochrane), and the 
search was restricted in time and language. Thus, it is safe to assume that not all 
literature describing causes of misdiagnosis of COPD was included in the review. 
 
6.2.3 PAPER III 
Paper III contributed a suggestion for adjustment of the pre-bronchodilator threshold 
for defining COPD. A strength of the study presented in Paper III was that it was 
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based on data from the NHANES dataset. NHANES has developed comprehensive 
spirometry standardized procedures assuring high quality spirometry assessments 
(122). 
 
The study presented in Paper III included only subjects between the ages of 40 and 79 
years. Thus, the results of Paper III may not apply to subjects under 40 years of age 
or to subjects above 79 years of age. Only a few subjects had very severe COPD. One 
may assume that patients with severe disease are less likely to participate in a 
comprehensive survey such as NHANES resulting in a less representative sample.  
The study diagnosis of COPD was based on spirometry alone, which represents a 
limitation. COPD ought to be considered in all potential patients with chronic cough, 
sputum production, dyspnea, and/or history of exposure to COPD risk factors (123). 
However, the NHANES questionnaires regarding respiratory symptoms were 
considered insufficient for diagnostic assessment in the study.  
6.2.4 PAPER IV 
Paper IV contributed a preliminary validation of the SPOT test as a future pulmonary 
function test for COPD. The study presented in Paper IV was the first to explore the 
validity of the SPOT test. The study was strengthened by the fact that a trained nurse 
with exhaustive experience in pulmonary function testing carried out the body 
plethysmography and the DLCO test. 
A limitation of the study was that only 14 subjects were included in the analysis. More 
subjects would have strengthened the results. Moreover, all data related to the SPOT 
test were registered manually, which increase the risk of registration errors. The risk 
of manual error was accommodated by the fact that two researchers always performed 
the SPOT test. 
 
6.3 DISCUSSION OF RESULTS 
The results of the four thesis papers will be discussed in the succeeding sections. 
6.3.1 UNDERDIAGNOSIS OF COPD 
In line with Paper I, previous publications have explored the characteristics of subjects 
with undiagnosed COPD. The results of Paper I may be compared to a study by 
Martinez et al. (2015), which was based on data from NHANES as well. Martinez et 
al. (2015) identified the following factors characterizing undiagnosed COPD: female 
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sex, higher age, lower BMI, fewer respiratory symptoms, and higher FEV1 (25). In 
line herewith, Hvidsten et al. (2010) found that characteristics of subjects with 
undiagnosed COPD included a more positive self-rated health condition and a better 
lung function, including respiratory symptoms (124). Santos et al. (2014), Balcells et 
al. (2015), and Lamprecht et al. (2015) also found that undiagnosed COPD was 
characterized by less severe disease (15,26,125). The study by Lamprecht et al. (2015) 
also distinguishes from Paper I, because their undiagnosed subjects were 
characterized by younger age, male sex, and lower education (15). However, these 
additional studies treating characteristics of undiagnosed COPD overall agree with 
the results of Paper I, as subjects with undiagnosed COPD seems to be characterized 
by better lung function and less severe respiratory symptoms than their undiagnosed 
counterparts. However, the literature still needs to determine the significance of 
additional characteristics; including age, educational level, and income. This 
statement is supported by a review by Han et al. (2015) who found that variables such 
as education, occupation, and childhood illness are not included in COPD case-finding 
tools even though they may add value (126). 
There seems to be general agreement that the existing evidence base does not support 
the screening of patients without respiratory symptoms using spirometry (3,8,127). 
Even though pre-bronchodilator spirometry is relatively inexpensive, the economic 
and public health costs are considered too comprehensive for such a screening (8). 
However, active case finding may be relevant (3). A study by Moretz et al. (2015) 
developed and validated a predictive model aiming to identify patients with 
undiagnosed COPD. The optimal predictive model included 34 variables associated 
with a diagnosis of COPD. The model provided an acceptable level of accuracy (128). 
Such model shows an example of how characteristics associated with undiagnosed 
COPD may add to the identification of patients with undiagnosed COPD. A 
qualitative study by Leidy et al. (2015) identified 48 items that is to be tested 
quantitatively in a future study in combination with peak expiratory flow devises 
(129). In line herewith, Ronaldson et al. (2018) and Jihoo et al. (2013) suggest that 
COPD case finding may be improved by use of peak flow meters or microspirometers 
(130,131). Hence, it seems that development and optimization of COPD case-finding 
tools are in the pipeline.  
Paper I does not explain why the subjects with a post-bronchodilator FEV1/FVC<0.7 
were undiagnosed. Based on the results of Paper I, one may assume that mild 
representation of symptoms contributes to the underdiagnosis. However, it is not clear 
if the subjects remained undiagnosed because of an error in the diagnostic process or 
because the subjects had not seen a doctor. Mild representation of symptoms may 
cause a diagnostic delay until a more severe disease stage. The diagnostic delay may 
also be caused by lack of awareness and knowledge among healthcare professionals 
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(23). An example of this mild representation of symptoms is a study by Akamatsu et 
al. (2008). The authors found that 52% of their subjects did not have any respiratory 
symptoms despite having a COPD diagnosis (24). It must be presumed challenging to 
diagnose a patient with COPD if the patient does not complain about respiratory 
symptoms. Moreover, patients who are not bothered by respiratory symptoms may be 
less inclined to visit their general practitioner.  
6.3.2 MISDIAGNOSIS OF COPD 
As described in Paper II, there are several challenges linked to diagnosis of COPD. 
First, the patient in question needs to be identified, as described in Paper I. However, 
when a patient is identified and undergoes diagnostic evaluation, a multitude of 
diagnostic errors may occur in the process.  
The challenges linked to the spirometry threshold are well recognized. It is essential 
for limiting misdiagnoses that consensus is reached regarding the proper diagnostic 
criteria (132). The fixed threshold of 0.70 seems to cause overdiagnosis of older 
patients and underdiagnosis of younger patients (27,28,52,53,55–57,60–
66,68,72,78,79,81–83,133). However, Paper II did not find overall agreement that 
LLN should replace the fixed threshold of 0.7 (27,52,53,55,56,78,79,81,82). A 
shortcoming of the existing literature is the lack of a gold standard to which the 
threshold can be compared. Often, studies just compare LLN to 0.70 and vice versa. 
Hoesein et al. (2011) found that 9 of 18 studies used only LLN as reference test, which 
led to the conclusion that the choice between the fixed value and LLN could not be 
based on current literature (132). These findings are in agreement with the findings of 
Paper II. According to Hoesein et al. (2012), further longitudinal research is warranted 
in order to clarify the ideal threshold (132), but perhaps we should start seeking other 
options? Perhaps it is time to acknowledge that neither LLN nor 0.70 leads to a reliable 
COPD diagnosis. As demonstrated in Paper II, a great number of studies have 
questioned the threshold without reaching consensus.  
The challenges of spirometry in COPD diagnosis and monitoring do not confine to 
the spirometry threshold alone. Spirometry may be insufficient for classification of 
lung abnormalities – independent of the threshold used (134). Brusasco et al. (2015) 
recommends that spirometry should not be used as the only pulmonary function test 
in COPD (134). Moreover, Doherty (2008) argues that spirometry alone is inadequate 
to monitor COPD (6). These statements are supported by study by Schermer et al. 
(2016), in which 14.3% of subjects shifted diagnostic category over time when 
spirometry was used for the diagnostic determination (135). These findings are in line 
with the results of Paper II, where it was found that errors linked to spirometry is a 
significant cause of misdiagnosis of COPD. 
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Spirometry also proves problematic for smokers. Woodruff et al. (2016) found that 
respiratory symptoms and exacerbations were common among current or former 
smokers with spirometry values within the normal range. On that basis, Woodruff et 
al. (2016) suggests that the current use of spirometry may not be adequate for 
diagnosis of smoking-related lung disease (136). These findings are similar to the 
findings of Regan et al. (2015) who found that lung impairment and disease were 
common among smoking subjects without COPD as defined by spirometry (137). 
These challenges may add to the severe underdiagnosis of COPD. Along these lines, 
the study presented in Paper II also identified smoking as a patient-related factor 
contributing to misdiagnosis of COPD. 
Fourteen percent of the papers included in Paper II described misdiagnosis in cases of 
COPD with comorbidities (23,55,88,107–109,111–113). Comorbidities are common 
among patients with COPD (3) and aggravate the problem of misdiagnosis of patients 
with comorbidities. The challenge of differential diagnosis combined with the 
multifactorial challenges linked to spirometry may add to the fact that COPD 
misdiagnosis is also linked to the diagnostic practices of primary care. Primary care 
diagnosis is often discordant with a diagnosis made by a pulmonary specialist 
(84,86,87,90–92). Primary care should receive better diagnostic support than they do 
now (13, 57). Paper II found various setups designed for the support of primary care 
in the diagnosis of COPD (84,86,87,90–92). However, the ideal setup remains 
unclear. 
6.3.3 ADJUSTMENT OF BRONCHODILATOR SPIROMETRY 
Bronchodilator spirometry represents a challenge in COPD diagnosis as well. 
According to existing guidelines, COPD diagnosis should always be based on post-
bronchodilator spirometry (3). However, post-bronchodilator spirometry is not always 
performed, and a diagnosis is then established based on pre-bronchodilator spirometry 
(30,32). Thus, bronchodilator spirometry represents a cause of misdiagnosis of 
COPD, as described in Paper II. Paper III accommodates this issue by suggesting an 
adjustment of threshold from 0.7 to 0.66 for pre-bronchodilator spirometry. However, 
even though such an adjustment may improve diagnostic accuracy, it does not solve 
the issue of misdiagnosis of COPD. The suggested adjustment may be considered a 
consolidation rather than a solution to the challenges of spirometry-based diagnosis 
of COPD.  
The evidence regarding bronchodilator testing seems indecisive. A study by Mannino 
et al. (2011) found similar accuracy in pre- and post-bronchodilator spirometry for 
predicting mortality (138). Similarly, Hoesein et al. (2012) found no significant 
difference in diagnostic property between pre- or post-bronchodilator spirometry 
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(139). In contrast, Schermer et al. (2008) and Waheed et al. (2011) found that pre-
bronchodilator spirometry cause overestimation of airflow obstruction (83,105). In 
line herewith, Probst-Hensch et al. (2010) found that pre-bronchodilator spirometry 
may cause misclassification of COPD (104). Chen et al. (2012) found pre-
bronchodilator FEV1 to be inferior to post-bronchodilator FEV1 in the assessment of 
COPD severity (140). However, Fortis et al. (2017) found that post-bronchodilator 
spirometry may more accurately predict various COPD features and outcomes (141). 
Hence, the evidence for using bronchodilators seems less convincing. One may 
assume that part of the pre-bronchodilator misclassification is caused by the poor 
accuracy of the 0.7 threshold that was identified in Paper III. 
In summary, it may be questioned whether spirometry leads to a reliable diagnosis of 
COPD. The multifaceted challenges linked to spirometry clearly calls for alternative 
pulmonary function tests for COPD diagnosis and monitoring.  
 
6.3.4 PULMONARY FUNCTION TESTING ALTERNATIVES 
In general, pulmonary function tests depend on patient effort. This dependence is 
obviously an issue, as patient effort is impossible to standardize (35). The SPOT test 
is expected to be independent of patient effort, which underlines its potential for 
telemonitoring as well as diagnosis of COPD. As mentioned previously, pulmonary 
function tests are seldom included in COPD telemonitoring trials (44). Their exclusion 
may, in part, be explained by the complexity of the existing pulmonary function tests. 
Patients cannot perform neither spirometry nor DLCO without verbal instruction 
during the tests (34). Thus, due to its simplicity, the SPOT test has potential 
application in telemonitoring.  
Another challenge of existing pulmonary function tests is that it is very challenging 
to perform spirometry, body plethysmography, and DLCO with severe respiratory 
symptoms (34,119,142). Consequently, patients may be unable to perform pulmonary 
function tests during hospital admissions due to exacerbation. The SPOT test is not 
challenging to perform for patients in exacerbation and thus has potential application 
during hospital admission. 
Obviously, the correlation between DLCO and the SPOT test is imperfect. The 
deviations may partly be explained by the variability of DLCO. The equipment-
related variability of DLCO analyzers may comprise to 20% (143,144). Moreover, 
one should expect to see patient-related variability, equipment-related variability, and 
clinician-related variability. DLCO is also biased by smoking, and the existing DLCO 
guidelines do not compensate for carboxyhemoglobin sufficiently (38,145,146). 
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Smokers may have carboxyhemoglobin levels above 10%, whereas the 
carboxyhemoglobin level of healthy nonsmokers typically lies below 2%. When the 
carboxyhemoglobin level increases by 1%, it will cause a decrease of approximately 
1% in DLCO (147). Carboxyhemoglobin may explain the variability of the smoking 
subjects included in Paper IV. The challenges related to DLCO obviously represents 
an issue when the SPOT test is assessed by using DLCO as a gold standard.  
Paper IV found a poor correlation between FEV1 and the SPOT test and DLCO, 
respectively. These findings combined with the findings of Paper I-III underlines that 
COPD is highly challenging to diagnose. Patients with COPD may be affected more 
or less by emphysema or small airways disease (3) which complicate the diagnostic 
process. Although spirometry should not be used alone to diagnose and monitor 
COPD (133,134), it continues to be the key pulmonary function test in COPD. The 
SPOT test may serve as a potential supplement to spirometry in the diagnostic 
assessment. One may cautiously suggest that the SPOT test provides an estimate of 
level of emphysema, whereas spirometry may primarily provide an estimate of the 
level of chronic bronchitis. Such a combination would provide a more holistic 
approach when assessing lung function in COPD. We should not expect any 
pulmonary function test to stand alone in the diagnosis and monitoring of a disease as 
complex as COPD.  
 
6.4 FUTURE PERSPECTIVES 
COPD case finding can be optimized. As described, it seems that development and 
optimization of COPD case-finding tools are in the pipeline. This optimization may, 
among other things, focus on determining the role of specific characteristics of 
patients with undiagnosed COPD. The role of characteristics such as edema, 
peripheral artery disease, history of lower tract infection, educational level, age, 
income, occupation, and childhood illness is yet to be determined. Moreover, the role 
of flow meters in COPD case finding is also uncertain. Future studies may focus on 
algorithms based on characteristics of undiagnosed COPD in combination with flow 
meter testing in order to identify the optimal approach in COPD case finding. 
To minimize cases of underdiagnosed or misdiagnosed COPD, the respiratory 
community needs to agree on the definition of COPD and on the threshold for defining 
COPD. One cannot expect primary care to determine a correct diagnosis on a fragile 
foundation. It is essential that future studies determine how to optimize the support of 
primary care in COPD diagnosis. Moreover, the evidence regarding bronchodilator 
spirometry seems unclear, and additional studies should explore the necessity of 
bronchodilator testing in COPD diagnosis. Further studies of the adjusted pre-
CHAPTER 6: DISCUSSION 
59 
 
bronchodilator threshold of 0.66 suggested in Paper III would also add value, since 
post-bronchodilator spirometry is seldom performed in clinical practice.  
As spirometry seems to be the main cause of misdiagnosis of COPD, future research 
should focus on alternative pulmonary function tests and biomarkers. Such research 
may focus on the SPOT test, but the potential of other pulmonary function tests and 
biomarkers should be explored as well. COPD is multifaceted, and we should not 
expect a single, isolated test to be able to determine diagnosis and disease progression.  
Finally, future studies may determine the validity of the SPOT test as a future 
pulmonary function test for COPD. First, more subjects should undergo more or less 
the same procedure as that the 14 subjects who were included in Paper IV. Second, a 
study should aim to explore the potential of SPOT as a predictor of COPD 
exacerbation for potential implementation in telemedicine setups. This process would 
involve SPOT measurements in patients hospitalized for exacerbation compared to 
six weeks later when their condition has stabilized. Such studies should account for 
known biases such as carboxyhemoglobin. A study protocol for such a study has 
already been approved by the local ethical committee in the North Denmark Region. 
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CHAPTER 7: CONCLUSION 
This chapter concludes the thesis. 
In conclusion, the diagnosis of COPD proves challenging. Patients with COPD, who 
remain undiagnosed, are characterized by fewer respiratory symptoms and overall 
better health than their diagnosed counterparts. This challenge complicates the 
diagnostic process, as it may be difficult to identify patients with mild respiratory 
symptoms. Moreover, the diagnostic process is characterized by a multitude of causes 
of misdiagnosis. These causes of misdiagnosis are mainly linked to the key pulmonary 
function test in COPD – spirometry. Especially the threshold for defining COPD is 
heavily discussed as a cause of misdiagnosis of COPD. 
COPD diagnosis may be improved by adjusting the pre-bronchodilator threshold of 
FEV1/FVC<0.7. An adjustment of the threshold to 0.66 may improve the diagnostic 
accuracy. However, the need for alternative pulmonary function tests in COPD is 
clear. The SPOT test is a novel pulmonary function test in COPD. The test correlated 
significantly with DLCO. Thus, the SPOT test seems promising as a future pulmonary 
function test for COPD. However, further validation of the SPOT test is needed. The 
role of the SPOT test in COPD diagnosis and monitoring is yet to be determined. 
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